newsfilter
← Interviews
a16z27 min

Biotech CEO on where we are in the fight to cure cancer

Jonathan Lim, Jorge

Interview, Fireside Chat

Former Halozyme CEO Jonathan Lim leverages his experience scaling biotech startups to lead Araska Therapeutics, a company targeting the historically undruggable RAS pathway with a pipeline including the pan-RAF inhibitor Naporafenib. Concurrently, his family office, City Hill Ventures, manages a diversified portfolio of life sciences assets and media projects that parallel the high-risk, high-reward dynamics of pharmaceutical development. Lim's strategy emphasizes capital preservation and the combination of novel molecular glues with standard therapies to drive long-term remission rates beyond current limits in pancreatic, lung, and colon cancers.